Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2

Scand J Rheumatol. 2021 May;50(3):243-245. doi: 10.1080/03009742.2020.1772868. Epub 2020 Jul 28.

Authors

D Keino^{1

2}, K Kondoh¹, Y Kim¹, A Sudo¹, R Ohyama¹, M Morimoto¹, H Nihira³, K Izawa³, S Iwaki-Egawa⁴, T Mori¹, A Kinoshita¹

Affiliations

¹ Department of Pediatrics, St Marianna University School of Medicine Hospital, Kanagawa, Japan.
² Division of Hematology and Oncology, Kanagawa Children`s Medical Center, Yokohama, Japan.
³ Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan.
⁴ Department of Life Sciences, Hokkaido Pharmaceutical University School of Pharmacy, Hokkaido, Japan.

PMID: 32720851
DOI: 10.1080/03009742.2020.1772868

No abstract available

Publication types

Case Reports

MeSH terms

Adenosine Deaminase / deficiency*
Adenosine Deaminase / genetics
Adolescent
Agammaglobulinemia / drug therapy*
Agammaglobulinemia / genetics
Cyclosporine / therapeutic use*
Etanercept / therapeutic use*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Intercellular Signaling Peptides and Proteins / genetics
Severe Combined Immunodeficiency / drug therapy*
Severe Combined Immunodeficiency / genetics
Treatment Outcome
Tumor Necrosis Factor Inhibitors / therapeutic use*

Substances

Immunosuppressive Agents
Intercellular Signaling Peptides and Proteins
Tumor Necrosis Factor Inhibitors
Cyclosporine
ADA2 protein, human
Adenosine Deaminase
Etanercept

Supplementary concepts

Severe combined immunodeficiency due to adenosine deaminase deficiency